Gabriela Trifan

Gabriela Trifan

Auto-generated profile, based on publicly available information

Gabriela Trifan

Department of Neurology and Rehabilitation University of Illinois Chicago USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
GTGabriela Trifan
Gabriela Trifan
FTFernando D Testai
Fernando D Testai

1 January 2012 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
EHE. Mark Haacke
E. Mark Haacke
WFWei Feng
Wei Feng
DUDavid Utriainen
David Utriainen
GTGabriela Trifan
Gabriela Trifan
ZWZhen Wu
Zhen Wu
DHDavid Hubbard
David Hubbard

12 March 2019 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
GTGabriela Trifan
Gabriela Trifan
BABaback Arshi
Baback Arshi
FTFernando D. Testai
Fernando D. Testai
Background/Objective: Intraventricular hemorrhage (IVH) extension after spontaneous supratentorial intracerebral hemorrhage (sICH) is an independent predictor of worse outcome. However, there is a paucity of data looking at the degree of IVH severity and its impact on outcome. This study addresses the contribution of IVH severity to outcome at time of hospital discharge after sICH. Methods: Two hundred and ten patients were included in the study. Baseline demographic and radiologic characteristics were abstracted. First available CT scans were reviewed for hematoma volume and location, IVH extension and presence of hydrocephalus (HCP). IVH severity was calculated using Graeb scale. Multivariate logistic regression models were developed to investigate the association of IVH severity with poor outcomes at hospital discharge, defined as modified Rankin scale score (mRS) >3. Results: Fifty-three percent of patients had IVH extension while 18% had surgical procedures done. Poor outcome (mRS >3) was seen for 56% of patients. Median IVH extension severity on the Graeb scale was two. Presence of IVH was associated with poor outcome in univariate and multivariate analysis (p < 0.005). Compared to patients with no IVH, IVH severity influenced outcome only when Graeb scores were ≥5 (OR = 1.3, 95% CI 0.49–3.23, p = 0.63, and OR = 2.9, 95% CI, 1.1–7.6, p = 0.03 for Graeb <5 and ≥5, respectively. Conclusions: Higher IVH severity (defined as Graeb score ≥5) is associated with worse outcome at time of hospital discharge, while lower IVH severity (Graeb scores 1–4) has similar outcomes to patients without IVH. IVH severity should be used in favor of IVH presence for prognostication purposes.

1 April 2017 in Magnetic Resonance Imaging
Verified
Journal Article
Closed access
GTGabriela Trifan
Gabriela Trifan
RGRamtilak Gattu
Ramtilak Gattu
EHEwart Mark Haacke
Ewart Mark Haacke
ZKZhifeng Kou
Zhifeng Kou
RBRandall R. Benson
Randall R. Benson

29 March 2022 in Neurology
Verified
Journal Article
Closed access
PDF file
GTGabriela Trifan
Gabriela Trifan
JBJose Biller
Jose Biller
FTFernando D Testai
Fernando D Testai
Background and Purpose: Current guidelines recommend the use of mechanical thrombectomy (MT) plus intravenous thrombolysis (aka bridging therapy, [BT]) for patients with anterior circulation large vessel occlusion (LVO) stroke. However, clinical equipoise exists in relation to the use of BT versus MT alone. Our objective is to compare the efficacy and safety of BT to MT for anterior circulation LVO. Methods: A systematic search of biomedical literature databases was performed from inception to October 29, 2021 to identify prospective and retrospective studies comparing the rates for functional independence (modified Rankin Scale score 0-2) and mortality at 90 days, symptomatic hemorrhage (sICH), and successful recanalization rates for MT and BT. Effect size was represented by odds ratio (OR) and analysis was done using random effects meta-analysis. Heterogeneity was assessed by I2 and Cochrane’s Q statistics. Results: Overall, 41 studies with 14885 patients were included. Mean age ± standard deviation (years) was 69±11 for BT and 70±11 for MT. All studies used alteplase as thrombolytic agent. BT group had 29% higher odds for functional independence (OR=1.29, 95% CI 1.16-1.44, I2=42%), 25% higher odds of successful reperfusion (OR=1.25, 95% CI=1.08-1.44, I2=42%) and a 31% decrease in odds for mortality (OR=.69, 95% CI .60-.80, I2=47%) compared with MT. sICH prevalence was similar between groups (OR=1.10, 95% CI=.95-1.28, I2=0%). Six of the studies were randomized clinical trials (RCT) with intention-to-treat analysis done in patients presenting directly to MT-capable centers. When analysis was restricted to these six RCT (n= 2333), no differences were observed in functional independence (OR=1.08, 95% CI=.91-1.27, I2=0%), sICH (OR=1.37, 95% CI=.95-1.97, I2=0%) or mortality (OR=.93, 95% CI=.74-1.16, I2=0%) between groups. However, successful reperfusion favored BT group (OR=1.35, 95% CI=1.06-1.73, I2=0%). Discussion: The odds for functional independence, successful reperfusion and mortality for the entire dataset favored the use of BT over MT (medium heterogeneity and low quality of the evidence). When analysis was restricted to RCT, both treatments had similar functional and safety outcomes (no heterogeneity), but recanalization rates favored BT group (no heterogeneity). Because these findings may differ in patients that present to non-MT-capable centers or with the use of other thrombolytic agents, further RCTs are needed.

22 June 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
GTGabriela Trifan
Gabriela Trifan
PGPhilip B Gorelick
Philip B Gorelick
FTFernando D Testai
Fernando D Testai
Background: Dual antiplatelet treatment (DAPT) with aspirin plus clopidogrel for a limited time is recommended after minor noncardioembolic stroke. Methods: We performed a meta-analysis of all major studies that compared the efficacy and safety of DAPT versus monotherapy for the secondary prevention of recurrent stroke or transient ischemic attack. The primary outcomes were stroke and the composite of stroke, transient ischemic attack, acute coronary syndrome, and death from any cause. The safety outcome was major hemorrhage. Relative risk (RR) and 95% CIs were calculated. Heterogeneity was assessed by I 2 and Cochrane Q statistics. Results: The analysis included 27 358 patients, the quality of evidence was moderate to low, and the heterogeneity for all the comparisons was low ( I 2 ≤25%). Compared with monotherapy, DAPT reduced the risk of recurrent stroke (RR, 0.71 [95% CI, 0.63–0.81]) and composite outcome (RR, 0.76 [95% CI, 0.69–0.83]) but increased the risk of major bleeding (RR, 2.17 [95% CI, 1.45–3.25]). In the subgroup analysis, ≤30 days of DAPT increased the risk of hemorrhage relative to monotherapy (RR, 1.94 [95% CI, 1.08–3.52]). In the sensitivity analysis, the risk for hemorrhage with ≤30 days of DAPT after excluding the combination of aspirin plus ticagrelor was comparable to monotherapy (RR, 1.42 [95% CI, 0.77–2.60]). However, the risk for stroke recurrence and composite outcomes in the subgroup and sensitivity analyses remain decreased compared with monotherapy. Conclusions: DAPT decreases the risk of recurrent stroke and composite events compared with monotherapy. DAPT increases the risk of major hemorrhage, except if the treatment is limited to 30 days and does not include the combination of aspirin plus ticagrelor.